Human Genome Rejects GSK's $2.6B Bid With Poison Pill

Law360, New York (May 17, 2012, 7:30 PM ET) -- Drugmaker Human Genome Sciences Inc. has blocked an unsolicited $2.59 billion takeover bid by GlaxoSmithKline PLC on Thursday with a poison pill plan that will deter the health care giant from taking a stake larger than 15 percent.

The board of Human Genome, which makes gene-targeting drugs, said it unanimously rejected the offer, for a second time, and set in place a short-term stockholder rights plan that will dilute the holdings of any purchaser of more than 15 percent of the company's stock, who does so...
To view the full article, register now.